Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Malignant Melanoma

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 54 articles: HTML format

Single Articles

September 2025
1. SATO T, Butler MO, Piperno-Neumann S, Hassel JC, et al
   Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 patients.
   Clin Cancer Res. 2025 Sep 12. doi: 10.1158/1078-0432.CCR-25-1513.
   PubMed     Abstract available
   
   
   
2. VERGARA IA, Maher NG, Potter AJ, Paver EC, et al
   Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors.
   Clin Cancer Res. 2025;31:3742-3753.
   PubMed     Abstract available
   
   
   August 2025
3. NOH KW, Tolkach Y, Helbig D, Mitchell Barroso V, et al
   Multimodal approach predicts relapse upon cessation of immune checkpoint inhibitors in advanced melanoma.
   Clin Cancer Res. 2025 Aug 25. doi: 10.1158/1078-0432.CCR-25-0889.
   PubMed     Abstract available
   
   
   
4. FA'AK F, Coudray N, Jour G, Ibrahim M, et al
   Artificial Intelligence Algorithm Predicts Response to Immune Checkpoint Inhibitors.
   Clin Cancer Res. 2025;31:3526-3536.
   PubMed     Abstract available
   
   
   July 2025
5. RIBAS A, Milhem MM, Hoimes CJ, Amin A, et al
   Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naive Advanced Melanoma.
   Clin Cancer Res. 2025 Jul 25. doi: 10.1158/1078-0432.CCR-25-0987.
   PubMed     Abstract available
   
   
   
6. HU L, Fan C, Bross P, Das A, et al
   FDA approval summary: Lifileucel for unresectable or metastatic melanoma previously treated with an anti-PD-1 based immunotherapy.
   Clin Cancer Res. 2025 Jul 23. doi: 10.1158/1078-0432.CCR-25-0880.
   PubMed     Abstract available
   
   
   
7. LIPSON EJ, Dolfi S, Tang H, Tawbi HA, et al
   Unravelling relatlimab-specific biology using biomarker analyses in patients with advanced melanoma in RELATIVITY-047.
   Clin Cancer Res. 2025 Jul 3. doi: 10.1158/1078-0432.CCR-24-2499.
   PubMed     Abstract available
   
   
   June 2025
8. DAVAR D, Eroglu Z, Perez CL, Di Pace B, et al
   Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A.
   Clin Cancer Res. 2025 Jun 24:OF1-OF10. doi: 10.1158/1078-0432.CCR-25-0884.
   PubMed     Abstract available
   
   
   
9. BHANJA D, Zhu J, Wilding H, Benavides-Vasquez J, et al
   A population-level real-world analysis and single-center validation of melanoma brain metastasis epidemiology following dual-agent immunotherapy.
   Clin Cancer Res. 2025 Jun 2. doi: 10.1158/1078-0432.CCR-24-2681.
   PubMed     Abstract available
   
   
   May 2025
10. FLAHERTY KT, Aplin AE, Davies MA, Hacohen N, et al
    Facts & Hopes: towards the next quantum leap in melanoma.
    Clin Cancer Res. 2025 May 23. doi: 10.1158/1078-0432.CCR-25-0278.
    PubMed     Abstract available
    
    
    
11. TARHINI AA, Obermayer A, Lee SJ, LaFramboise WA, et al
    Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-Risk Melanoma.
    Clin Cancer Res. 2025 May 20. doi: 10.1158/1078-0432.CCR-24-3980.
    PubMed     Abstract available
    
    
    
12. VERDEGAAL EME, Verpoorte ALC, van der Kooij MK, de Bruin L, et al
    Effective TIL therapy for patients with checkpoint-resistant melanoma without lymphodepleting regimens requires interferon-alpha.
    Clin Cancer Res. 2025 May 6. doi: 10.1158/1078-0432.CCR-24-4322.
    PubMed     Abstract available
    
    
    April 2025
13. LI Y, Cui Z, Song X, Chen Y, et al
    Single-cell transcriptomic landscape deciphers intratumoral heterogeneity and subtypes of acral and mucosal melanoma.
    Clin Cancer Res. 2025 Apr 7. doi: 10.1158/1078-0432.CCR-24-3164.
    PubMed     Abstract available
    
    
    March 2025
14. DUMMER R, Sandhu S, Miller WH, Butler MO, et al
    Longitudinal Genomic Analysis to Fine-Tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients With BRAF V600-Mutant Metastatic Melanoma.
    Clin Cancer Res. 2025 Mar 19. doi: 10.1158/1078-0432.CCR-24-0254.
    PubMed     Abstract available
    
    
    
15. LI X, Zhang X, Zhao S, Pei S, et al
    The dynamically evolving cell states and ecosystem from benign nevi to melanoma.
    Clin Cancer Res. 2025 Mar 17. doi: 10.1158/1078-0432.CCR-24-2971.
    PubMed     Abstract available
    
    
    February 2025
16. WANG C, Niu X, Xia T, Wang P, et al
    Predicting c-KIT Inhibitor Efficacy in Patient-Derived Models of Sinonasal Mucosal Melanomas through Integrated Histogram Analysis of Whole-Tumor DKI, IVIM, and DCE-MRI.
    Clin Cancer Res. 2025 Feb 12. doi: 10.1158/1078-0432.CCR-24-3765.
    PubMed     Abstract available
    
    
    December 2024
17. FISCHER GM, Lamba N, Vogelzang J, Aizer A, et al
    Genomic profiling reveals SMARCA4 mutations are associated with shorter overall and intracranial progression free survival in melanoma brain metastasis patients.
    Clin Cancer Res. 2024 Dec 30. doi: 10.1158/1078-0432.CCR-24-0301.
    PubMed     Abstract available
    
    
    
18. LEE S, Hamid O, Jotte R, Zakharia Y, et al
    Phase 2 Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1 Pretreated Metastatic Non-Small Cell Lung Cancer and Metastatic Cutaneous Melanoma.
    Clin Cancer Res. 2024 Dec 30. doi: 10.1158/1078-0432.CCR-24-1478.
    PubMed     Abstract available
    
    
    October 2024
19. TARHINI AA, Eroglu Z, Eljilany I, Zager JS, et al
    Neoadjuvant intratumoral plasmid interleukin-12 electro-gene-transfer and nivolumab in patients with operable locoregionally advanced melanoma.
    Clin Cancer Res. 2024 Oct 17. doi: 10.1158/1078-0432.CCR-24-2768.
    PubMed     Abstract available
    
    
    
20. GIDE TN, Mao Y, Scolyer RA, Long GV, et al
    Tissue-based Profiling Techniques to Achieve Precision Medicine in Cancer: Opportunities and Challenges in Melanoma.
    Clin Cancer Res. 2024 Oct 7. doi: 10.1158/1078-0432.CCR-24-1109.
    PubMed     Abstract available
    
    
    September 2024
21. MA KL, Mitchell TC, Dougher M, Sharon CE, et al
    Tumor-infiltrating lymphocytes in necrotic tumors after melanoma neoadjuvant anti-PD1 therapy correlate with pathological response and recurrence-free survival.
    Clin Cancer Res. 2024 Sep 9. doi: 10.1158/1078-0432.CCR-23-3775.
    PubMed     Abstract available
    
    
    August 2024
22. SMITHY JW, Kalvin HL, Ehrich FD, Shah R, et al
    Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study.
    Clin Cancer Res. 2024;30:3407-3415.
    PubMed     Abstract available
    
    
    
23. MONSON KR, Ferguson R, Handzlik JE, Xiong J, et al
    Tyrosine-protein kinase SYK-related gene signature in baseline immune cells associated with adjuvant immunotherapy-induced immune-related adverse events in melanoma.
    Clin Cancer Res. 2024 Aug 8. doi: 10.1158/1078-0432.CCR-24-0900.
    PubMed     Abstract available
    
    
    July 2024
24. YAKKALA C, Corria-Osorio J, Kandalaft L, Denys A, et al
    Cryoablation does not significantly contribute to systemic effector immune responses in poorly immunogenic B16F10 melanoma model.
    Clin Cancer Res. 2024 Jul 18. doi: 10.1158/1078-0432.CCR-24-0371.
    PubMed     Abstract available
    
    
    
25. ZHAO Y, Hu Z, Bathena SP, Keidel S, et al
    Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors.
    Clin Cancer Res. 2024;30:3050-3058.
    PubMed     Abstract available
    
    
    
26. STINSON JA, P Barbosa MM, Sheen A, Momin N, et al
    Tumor-localized interleukin-2 and interleukin-12 combine with radiation therapy to safely potentiate regression of advanced malignant melanoma in pet dogs.
    Clin Cancer Res. 2024 Jul 9. doi: 10.1158/1078-0432.CCR-24-0861.
    PubMed     Abstract available
    
    
    June 2024
27. AUNG TN, Warrell J, Martinez-Morilla S, Gavrielatou N, et al
    Spatially informed gene signatures for response to immunotherapy in melanoma.
    Clin Cancer Res. 2024 Jun 5. doi: 10.1158/1078-0432.CCR-23-3932.
    PubMed     Abstract available
    
    
    
28. D'ALISE AM, Leoni G, Cotugno G, Siani L, et al
    Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses.
    Clin Cancer Res. 2024;30:2412-2423.
    PubMed     Abstract available
    
    
    May 2024
29. VENTIN M, Cattaneo G, Arya S, Jia J, et al
    Chimeric Antigen Receptor T Cell with an Inducible Caspase 9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting.
    Clin Cancer Res. 2024 May 20. doi: 10.1158/1078-0432.CCR-24-0071.
    PubMed     Abstract available
    
    
    
30. EMBABY A, Huijberts SCFA, Wang L, Leite de Oliveira R, et al
    A proof-of-concept study of sequential treatment with the HDAC inhibitor vorinostat following BRAF and MEK inhibitors in BRAFV600mutated melanoma.
    Clin Cancer Res. 2024 May 13. doi: 10.1158/1078-0432.CCR-23-3171.
    PubMed     Abstract available
    
    
    January 2024
31. ANDERSON TM, Chang BH, Huang AC, Xu X, et al
    FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma.
    Clin Cancer Res. 2024 Jan 24:OF1-OF10. doi: 10.1158/1078-0432.CCR-23-2390.
    PubMed     Abstract available
    
    
    November 2023
32. SHEN A, Arbesman M, Lodha R, Rayman P, et al
    Clinical and Immunologic Features of Germline Pathogenic Variant (gPV) Positive Patients with Melanoma.
    Clin Cancer Res. 2023 Nov 30. doi: 10.1158/1078-0432.CCR-23-1964.
    PubMed     Abstract available
    
    
    October 2023
33. PATEL SP, Othus M, Chae YK, Dennis MJ, et al
    A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in patients with gestational trophoblastic neoplasia.
    Clin Cancer Res. 2023 Oct 26. doi: 10.1158/1078-0432.CCR-23-2293.
    PubMed     Abstract available
    
    
    
34. ZILA N, Eichhoff OM, Steiner I, Mohr T, et al
    Proteomic profiling of advanced melanoma patients to predict therapeutic response to anti-PD-1 therapy.
    Clin Cancer Res. 2023 Oct 20. doi: 10.1158/1078-0432.CCR-23-0562.
    PubMed     Abstract available
    
    
    
35. MITRA A, Thompson B, Strange A, Amato CM, et al
    A Population of Tumor-Infiltrating CD4+ T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance.
    Clin Cancer Res. 2023;29:4242-4255.
    PubMed     Abstract available
    
    
    
36. BETOF WARNER A, Luke JJ
    CD4+ TIL to the Rescue of Anti-PD-1 Failure by Targeting MHC-II.
    Clin Cancer Res. 2023;29:3829-3831.
    PubMed     Abstract available
    
    
    September 2023
37. MONBERG TJ, Borch TH, Svane IM, Donia M, et al
    TIL Therapy: Facts and Hopes.
    Clin Cancer Res. 2023;29:3275-3283.
    PubMed     Abstract available
    
    
    August 2023
38. VAN DEN BULK J, Verdegaal EME, van der Ploeg M, Visser M, et al
    Neoantigen targetability in progressive advanced melanoma.
    Clin Cancer Res. 2023 Aug 4:CCR-23-1106. doi: 10.1158/1078-0432.CCR-23-1106.
    PubMed     Abstract available
    
    
    
39. WEISS SA, Sznol M, Shaheen M, Berciano-Guerrero MA, et al
    A Phase II Trial of the CD40 Agonist Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Disease Progression on Anti-PD-1.
    Clin Cancer Res. 2023 Aug 3:CCR-23-0475. doi: 10.1158/1078-0432.CCR-23-0475.
    PubMed     Abstract available
    
    
    July 2023
40. SMITHY JW, Luke JJ
    CD16+ Macrophages: An Emerging Biomarker for Combined CTLA-4 and PD-1 Blockade.
    Clin Cancer Res. 2023;29:2345-2347.
    PubMed     Abstract available
    
    
    June 2023
41. AUGUSTIN RC, Luke JJ
    PD1 monotherapy reigns supreme in adjuvant melanoma...but for how long?
    Clin Cancer Res. 2023 Jun 28:CCR-23-1194. doi: 10.1158/1078-0432.CCR-23-1194.
    PubMed     Abstract available
    
    
    
42. ELLINGSEN EB, O'Day S, Mezheyeuski A, Gromadka A, et al
    Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Advanced Melanoma: Results from a Phase I Trial.
    Clin Cancer Res. 2023 Jun 28:CCR-23-0416. doi: 10.1158/1078-0432.CCR-23-0416.
    PubMed     Abstract available
    
    
    
43. TOKER J, Iorgulescu JB, Ling AL, Villa GR, et al
    Clinical Importance of the lncRNA NEAT1 in Cancer Patients Treated with Immune Checkpoint Inhibitors.
    Clin Cancer Res. 2023;29:2226-2238.
    PubMed     Abstract available
    
    
    
44. FOX BA, Urba WJ, Jensen SM, Page DB, et al
    Cancer's Dark Matter: Lighting the Abyss Unveils Universe of New Therapies.
    Clin Cancer Res. 2023;29:2173-2175.
    PubMed     Abstract available
    
    
    
45. STINSON JA, Sheen A, Momin N, Hampel J, et al
    Collagen-Anchored Interleukin-2 and Interleukin-12 Safely Reprogram the Tumor Microenvironment in Canine Soft-Tissue Sarcomas.
    Clin Cancer Res. 2023;29:2110-2122.
    PubMed     Abstract available
    
    
    May 2023
46. HOROWITCH B, Lee DY, Ding M, Martinez-Morilla S, et al
    Subsets of interferon signaling predict response to immune checkpoint blockade in melanoma patients.
    Clin Cancer Res. 2023 May 26:CCR-23-0215. doi: 10.1158/1078-0432.CCR-23-0215.
    PubMed     Abstract available
    
    
    
47. STUPIA S, Heeke C, Bruggemann A, Zaremba A, et al
    HLA class II loss and JAK1/2 deficiency coevolve in melanoma leading to CD4 T cell and IFNgamma cross-resistance.
    Clin Cancer Res. 2023 May 18:CCR-23-0099. doi: 10.1158/1078-0432.CCR-23-0099.
    PubMed     Abstract available
    
    
    
48. FANE ME, Ecker BL, Kaur A, Marino GE, et al
    Correction: sFRP2 Supersedes VEGF as an Age-related Driver of Angiogenesis in Melanoma, Affecting Response to Anti-VEGF Therapy in Older Patients.
    Clin Cancer Res. 2023;29:2012.
    PubMed    
    
    
    
49. DRAGHI A, Presti M, Jensen AWP, Chamberlain CA, et al
    Uncoupling CD4+ TIL-mediated tumor killing from JAK-signaling in melanoma.
    Clin Cancer Res. 2023 May 1:CCR-22-3853. doi: 10.1158/1078-0432.CCR-22-3853.
    PubMed     Abstract available
    
    
    April 2023
50. LARKIN J, Del Vecchio M, Mandala M, Gogas H, et al
    Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238.
    Clin Cancer Res. 2023 Apr 14:CCR-22-3145. doi: 10.1158/1078-0432.CCR-22-3145.
    PubMed     Abstract available
    
    
    
51. OLSON DJ, Luke JJ
    Myeloid Maturity: ATRA to Enhance Anti-PD-1?
    Clin Cancer Res. 2023;29:1167-1169.
    PubMed     Abstract available
    
    
    March 2023
52. KOTTSCHADE LA, Pond GR, Olszanski AJ, Zakharia Y, et al
    SALVO: Single Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma.
    Clin Cancer Res. 2023 Mar 31:CCR-22-3207. doi: 10.1158/1078-0432.CCR-22-3207.
    PubMed     Abstract available
    
    
    
53. ROBERT C, Lebbe C, Lesimple T, Lundstrom E, et al
    Phase I Study of Androgen Deprivation Therapy in Combination with Anti-PD-1 in Melanoma Patients Pretreated with Anti-PD-1.
    Clin Cancer Res. 2023;29:858-865.
    PubMed     Abstract available
    
    
    
54. FENTON GA, Mitchell DA
    Cellular Cancer Immunotherapy Development and Manufacturing in the Clinic.
    Clin Cancer Res. 2023;29:843-857.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.